Sonoma Pharmaceuticals Inc(SNOA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 7:53 PM ET (Korea 11/7 09:53)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.22 | Insider Own | 0.44% | Shs Outstand | 4.8M | Perf Week | 0.91% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.8M | Perf Month | -4.31% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 2.31% | Short Float | 2.28% | Perf Quarter | -13.95% |
| Income | -0.00B | P/S | 0.24 | EPS this Y | - | Inst Trans | 1.06% | Short Ratio | 1.04 | Perf Half Y | -7.5% |
| Sales | 0.02B | P/B | 0.81 | EPS next 5Y | - | ROA | -13.85% | Short Interest | 0.11M | Perf YTD | -69.51% |
| Book/sh | 1.38 | P/C | 0.99 | EPS past 3/5Y | 60.4% 47.5% | ROE | -42.52% | 52W High | -71.9% ($3.95) | Perf Year | -69.59% |
| Cash/sh | 1.12 | P/FCF | - | Sales past 3/5Y | 13.74% 0.95% | ROIC | -32.19% | 52W Low | 30.57% ($0.85) | Perf 3Y | -67.56% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 50.49% | Gross Margin | 38.91% | Volatility(W/M) | 7.04% 6.39% | Perf 5Y | -99.05% |
| Dividend TTM | - | EV/Sales | 0.03 | Sales Y/Y TTM | 47% | Oper. Margin | -6.41% | ATR (14) | 0.07 | Perf 10Y | -99.86% |
| Dividend Ex-Date | - | Quick Ratio | 2.29 | EPS Q/Q | 88.65% | Profit Margin | -10.33% | RSI (14) | 44.1 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.99 | Sales Q/Q | 59.55% | SMA20 | -2.42% ($1.14) | Beta | 1.29 | Target Price | $12 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/8/6 | SMA50 | -8.72% ($1.22) | Rel Volume | 0.43 | Prev Close | $1.07 |
| Employees | 259 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | - | SMA200 | -32.68% ($1.65) | Avg Volume(3M) | 0.10M | Price | $1.11 |
| IPO | 2007/1/25 | Option/Short | No/Yes | Trades | 104 | Volume | 44,527 | Change | 3.74% |
💊 A pharmaceutical company specializing in dermatology products. Wound and skin treatment products based on hypochlorous acid (HOCl). Holds patents for Q-Mycin technology. Currently expanding globally.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
SNOA has a sound balance sheet but weak earning power
Of every $100 in sales, $6.41 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $24. Peers typically go for $170. Compared with its own 2-year average, it is 91% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.0%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #74 of 83 in the industry
Based on market cap of $5M.
UPC#73 Universe Pharmaceuticals INC $7M PER - SNOA#74 Sonoma Pharmaceuticals Inc $5M PER - 
GELS#75 Gelteq Ltd $5M PER - 
YCBD#76 cbdMD Inc $5M PER - 
APUS#77 Apimeds Pharmaceuticals US Inc $4M PER - 
FAQ
What kind of company is SNOA?
SNOA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SNOA?
The market cap of SNOA is approximately $5M, ranking 5,583 within its sector.
What is the 52-week high and low for SNOA?
SNOA has recorded a 52-week high of $3.95 and a low of $0.85.
